Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160

Journal of Experimental and Clinical Cancer Research

Volumn 27, Issue 1, 2008, Pages

  Lu, Yi ^a   Yao, Hang Ping ^a   Wang, Ming Hai ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; RON RECEPTOR TYROSINE KINASE; RON160 RECEPTOR TYROSINE KINASE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; COMPLEMENTARY DNA; PROTEIN TYROSINE KINASE; RON PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL ACTIVITY; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DIMERIZATION; GENE DELETION; GENETIC VARIABILITY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL DIFFERENTIATION; CELL MOTION; CELL STRAIN 3T3; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PHOSPHORYLATION;

ANIMALS; BETA CATENIN; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; DNA, COMPLEMENTARY; GENETIC VARIATION; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NIH 3T3 CELLS; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 56349124223     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-27-55     Document Type: Article

References (33)

1. A novel putative receptor protein tyrosine kinase of the met family. C Ronsin F Muscatelli MG Mattei R Breathnach, Oncogene 1993 8 5 1195 1202 8386824
2. Identification of the ron gene product as the receptor for the human macrophage stimulating protein. MH Wang C Ronsin MC Gesnel L Coupeym A Skeel EJ Leonard R Breathnach, Science 1994 266 5182 117 119 10.1126/science.7939629 7939629
3. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. G Gaudino A Follenzi L Naldini C Collesi M Santoro KA Gallo PJ Godowski PM Comoglio, EMBO J 1994 13 15 3524 3532 8062829
4. Characterization of the DNF15S2 locus on human chromosome 3: identification of a gene coding for four kringle domains with homology to hepatocyte growth factor. S Han LA Stuart SJ Degen, Biochemistry 1991 30 40 9768 9780 10.1021/bi00104a029 1655021
5. The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. G Gaudino V Avantaggiato A Follenzi D Acampora A Simeone PM Comoglio, Oncogene 1995 11 12 2627 2637 8545120
6. The Ron/STK receptor tyrosine kinase is essential for peri-implantation development in the mouse. RS Muraoka WY Sun MC Colbert SE Waltz DP Witte JL Degen SJ Friezner Degen, J Clin Invest 1999 103 9 1277 12785 10225971 10.1172/JCI6091
7. Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. D Angeloni A Danilkovitch-Miagkova SV Ivanov R Breathnach BE Johnson EJ Leonard MI Lerman, Genes Chrom Cancer 2000 29 2 147 156 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.0.CO;2-N 10959094
8. The soluble sema domain of the RON receptor inhibits macrophage- stimulating protein-induced receptor activation. D Angeloni A Danilkovitch-Miagkova A Miagkov EJ Leonard MI Lerman, J Biol Chem 2004 279 5 3726 3732 10.1074/jbc.M309342200 14597639
9. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. C Collesi MM Santoro G Gaudino PM Comoglio, Mol Cell Biol 1996 16 10 5518 5526 8816464
10. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. MH Wang D Wang YQ Chen, Carcinogenesis 2003 24 8 1291 1300 10.1093/carcin/bgg089 12807733
11. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. MH Wang AL Kurtz YQ Chen, Carcinogenesis 2000 21 8 1507 1512 10.1093/carcin/21.8.1507 10910951
12. Altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity. X Wei L Hao S Ni Q Liu J Xu PH Correll, J Biol Chem 2005 280 48 40241 40251 10.1074/jbc.M506806200 16166096
13. Blocking Tumorigenic Activities of Colorectal Cancer Cells by a Splicing RON Receptor Variant Defective in the Tyrosine Kinase Domain. MH Wang WF Lao D Wang YL Luo HP Yao, Cancer Biol Ther 2007 6 7 1121 1129
14. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. C Ponzetto A Bardelli Z Zhen F Maina P dalla Zonca S Giordano A Graziani G Panayotou PM Comoglio, Cell 1994 77 2 261 271 10.1016/0092-8674(94)90318-2 7513258
15. The C terminus of RON tyrosine kinase plays an autoinhibitory role. N Yokoyama I Ischenko MJ Hayman WT Miller, J Biol Chem 2005 280 10 8893 8900 10.1074/jbc.M412623200 15632155
16. Requirement of both tyrosine residues 1330 and 1337 in the C-terminal tail of the RON receptor tyrosine kinase for epithelial cell scattering and migration. ZQ Xiao YQ Chen MH Wang, Biochem Biophys Res Commun 2000 267 2 669 675 10.1006/bbrc.1999.2011 10631120
17. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. JM O'Toole KE Rabenau K Burns D Lu V Mangalampalli P Balderes N Covino R Bassi M Prewett KJ Gottfredsen MN Thobe Y Cheng Y Li DJ Hicklin Z Zhu SE Waltz MJ Hayman DL Ludwig DS Pereira, Cancer Res 2006 66 18 9162 9170 10.1158/0008-5472.CAN-06-0283 16982759
18. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. MH Wang L Wei YL Luo HP Yao, J Pathol 2007 213 4 402 411 10.1002/path.2245 17955509
19. Overexpression of the RON gene in human breast carcinoma. P Maggiora S Marchio MC Stella M Giai A Belfiore M De Bortoli MF Di Renzo A Costantino P Sismondi PM Comoglio, Oncogene 1998 16 22 2927 33 10.1038/sj.onc.1201812 9671413
20. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. WY Lee HH Chen NH Chow WC Su PW Lin HR Guo, Clin Cancer Res 2005 11 6 2222 2228 10.1158/1078-0432.CCR-04-1761 15788670
21. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. CT Lee NH Chow PF Su SC Lin PC Lin JC Lee, Dis Colon Rectum 2008 51 8 1268 1274 10.1007/s10350-008-9297-1 18536971
22. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. HL Cheng HS Liu YJ Lin HH Chen PY Hsu TY Chang CL Ho TS Tzai NH Chow, Br J Cancer 2005 92 10 1906 1914 10.1038/sj.bjc.6602593 15870710
23. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. YQ Zhou C He YQ Chen D Wang MH Wang, Oncogene 2003 22 2 186 197 10.1038/sj.onc.1206075 12527888
24. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Y Lu HP Yao MH Wang, Cancer Lett 2007 257 2 157 164 10.1016/j.canlet.2007.08.007 17889431
25. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. XM Xu D Wang Q Shen YQ Chen MH Wang, Oncogene 2004 23 52 8464 8474 10.1038/sj.onc.1207907 15378025
26. Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase. XM Xu YQ Zhou MH Wang, J Biol Chem 2005 280 26 25087 25094 10.1074/jbc.M414699200 15878878
27. Collaborative activities of macrophage- stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. D Wang Q Shen YQ Chen MH Wang, Oncogene 2004 23 9 1668 1680 10.1038/sj.onc.1207282 15001985
28. The Ron oncogenic activity induced by the MEN2B-like substitution overcomes the requirement for the multifunctional docking site. MM Santoro L Penengo S Orecchia M Cilli G Gaudino, Oncogene 2000 19 45 5208 5211 10.1038/sj.onc.1203819 11064459
29. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. HP Yao YL Luo L Feng LF Cheng Y Lu W Li MH Wang, Cancer Biol Ther 2006 5 9 1179 1186 16880737
30. Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus. LD Finkelstein PA Ney QP Liu RF Paulson PH Correll, Oncogene 2002 21 22 3562 3570 10.1038/sj.onc.1205442 12032858
31. c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. L Penengo C Rubin Y Yarden G Gaudino, Oncogene 2003 22 24 3669 3679 10.1038/sj.onc.1206585 12802274
32. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. MM Santoro L Penengo M Minetto S Orecchia M Cilli G Gaudino, Oncogene 1998 17 6 741 749 10.1038/sj.onc.1201994 9715276
33. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. A Iwama N Yamaguchi T Suda, EMBO J 1996 15 21 5866 5875 8918464